SynthesisFrontiers in oncology2025
The prognostic value of miR-34 family in ovarian cancer: a systematic review and meta-analysis.
Synthesis in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The aim of this study was to evaluate the association between miR-34 family expression and overall survival (OS) and progression-free survival (PFS) in women with ovarian cancer. Methods: Literature searches were conducted using databases such as PubMed, Cochrane Library, EMBASE, Web of Science, Wanfang, and CNKI to identify studies reporting pooled hazard ratios (HRs) and 95% confidence intervals (CIs) examining the relationship between miR-34 family expression and overall survival (OS) or progression-free survival (PFS) in female patients with ovarian cancer. All potentially relevant studies were assessed and then pooled. Results: There were a total of seven literatures included in this systematic review and meta-analysis, which included 672 women. There was a significant improvement in survival for women with ovarian cancer when miR-34s expression was higher (OS, HR = 0.70, 95% CI:0.57-0.86; PFS, HR = 0.48, 95% CI:0.31-0.75). A subgroup analysis of miR-34 family members showed that differences between groups greatly affected PFS (HR = 0.50, 95% CI: 0.40-0.63). Conclusion: Based on the results of this review, it appears that ovarian cancer women with high expression of miR-34s may have a better chance of surviving.Systematic Review Registration: PROSPERO (CRD42024499203). Systematic review registration: https://www.crd.york.ac.uk/PROSPERO/, identifier CRD42024499203.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.